[PDF][PDF] Expert Recommendations on the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) from India: Current Perspective and Future Direction
BSPPH Kumar, S George, SMVGGN Gupta, K Makineni… - 2022 - academia.edu
Non-vitamin K antagonist oral anticoagulants (NOACs) are a new class of anticoagulant
drugs used in the prevention and treatment of venous thromboembolism (VTE) and atrial …
drugs used in the prevention and treatment of venous thromboembolism (VTE) and atrial …
[HTML][HTML] Expert recommendations on the usage of non-vitamin K antagonist oral anticoagulants (NOACs) from India: Current perspective and future direction
B Singh, P Pai, H Kumar, S George, S Mahapatra… - Cardiology and …, 2022 - Springer
Non-vitamin K antagonist oral anticoagulants (NOACs) are a new class of anticoagulant
drugs used in the prevention and treatment of venous thromboembolism (VTE) and atrial …
drugs used in the prevention and treatment of venous thromboembolism (VTE) and atrial …
State of play and future direction with NOACs: An expert consensus
AT Cohen, GY Lip, R De Caterina, H Heidbuchel… - Vascular …, 2018 - Elsevier
Atrial fibrillation (AF) and venous thromboembolism (VTE) are cardiovascular conditions
significant in contemporary practice. In both, the use of anticoagulation with vitamin K …
significant in contemporary practice. In both, the use of anticoagulation with vitamin K …
'Real world'use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry
JW Eikelboom, JI Weitz - Thrombosis and haemostasis, 2015 - thieme-connect.com
The non-vitamin K antagonist oral anticoagulants (NOACs) have been compared with
vitamin K antagonists (VKAs) in randomised controlled trials involving more than 150,000 …
vitamin K antagonists (VKAs) in randomised controlled trials involving more than 150,000 …
Expanding indications of nonvitamin K oral anticoagulants beyond nonvalvular atrial fibrillation and venous thromboembolism: a review of emerging clinical evidence
Direct oral anticoagulants (DOAC) have emerged as a new therapy for patients who need
and can tolerate oral anticoagulation. DOACs were initially approved for nonvalvular atrial …
and can tolerate oral anticoagulation. DOACs were initially approved for nonvalvular atrial …
[PDF][PDF] The Importance of Non-vitamin K Antagonists (NOAC) in Their Current Use
V Tosun - Current Researches in Health Sciences-III, 2023 - researchgate.net
Non-vitamin K oral anticoagulants are new drugs that are used in the treatment of atrial
fibrillation and venous thromboembolism. There are 4 NOACs in use today; dabigatran is a …
fibrillation and venous thromboembolism. There are 4 NOACs in use today; dabigatran is a …
Non–vitamin K antagonist oral anticoagulants, clinical use, real-world data, and reversal of anticoagulant effect
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in clinical practice
and is associated with a higher risk of thromboembolic events. CHA2DS2VASc score …
and is associated with a higher risk of thromboembolic events. CHA2DS2VASc score …
Non—Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation and Venous Thromboembolism: Where are we Now?
R Hajhosseiny, I Sabir, GYH Lip - Hospital practice, 2014 - Taylor & Francis
Four non-vitamin-K antagonist oral anticoagulants (NOACs) are now available and are
variously approved for stroke prevention in atrial fibrillation and the management of venous …
variously approved for stroke prevention in atrial fibrillation and the management of venous …
[HTML][HTML] Practical perspectives on the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation: a view …
AS Hersi, YS Alhebaishi, O Hamoui, T Hassan… - Journal of the Saudi …, 2018 - Elsevier
Clinical guidelines for the prevention of stroke in patients with nonvalvular atrial fibrillation
(NVAF) are available from several international cardiology associations. Patients with NVAF …
(NVAF) are available from several international cardiology associations. Patients with NVAF …
Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations
Warfarin, a vitamin K antagonist, is the most widely used oral anticoagulant in the world. It is
cheap and effective, but its use is limited in many patients by unpredictable levels of …
cheap and effective, but its use is limited in many patients by unpredictable levels of …